Everlywell Brings Clairity AI Breast Risk Tool Nationwide
Everlywell on Thursday, 1 October 2026, announced the nationwide commercial launch of Clairity Breast, an FDA-authorized AI five-year breast cancer risk assessment from routine mammograms.
PromptCrates Editorial
Staff Writer
Everlywell on Thursday, 1 October 2026, announced the nationwide commercial launch of Clairity Breast on its consumer platform, making an FDA-authorized AI assessment of five-year breast cancer risk available to women across the United States who have a qualifying recent screening mammogram, according to a Business Wire release carried by FinancialContent. Clairity Breast is described as the first FDA-authorized AI-driven software that can estimate a woman’s five-year risk of developing breast cancer from a routine screening mammogram. The partnership pairs Clairity, founded by radiologist Dr. Connie Lehman, with Everlywell, founded by Julia Cheek, and arrives during Breast Cancer Awareness Month after the tool previously had only limited health-system availability.
What Clairity Breast is authorized to estimate
Clairity Breast received FDA De Novo authorization in May 2025 for predicting five-year breast cancer risk from a standard screening mammogram. In 2026, updated NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Screening and Diagnosis introduced AI-based mammogram risk assessment as an option for identifying women at increased risk beginning at age 35, and Clairity Breast is included in those guidelines, the companies said. The release emphasizes a prevention framing: about 85% of breast cancers occur in women with no family history of the disease, so tools that extract risk signal from images women already receive could change who is offered intensified screening or risk-reduction counseling. Crucially, Clairity Breast does not screen for or detect existing cancer; it estimates future risk so a woman and her clinician can plan screening and risk-reduction options suited to her profile.
Validation numbers cited for authorization include more than 77,000 screening mammograms at five U.S. sites, with more than 120,000 mammograms across ten U.S. facilities after authorization. Until the Everlywell launch, availability ran through health systems such as Beth Israel Deaconess Medical Center in Massachusetts and Invision Sally Jobe in Colorado. Nationwide consumer access still routes through clinical guardrails: patients need a qualifying screening mammogram from the past twelve months, a licensed provider in Everlywell’s affiliated clinician network reviews and orders the assessment, and results are reviewed and released by a licensed provider with next steps based on national guidelines. Women can share results with their own clinicians, and Everlywell says its clinical team remains available for questions about a Clairity Breast result.
Why consumer distribution changes access math
Health-system deployments matter for workflow integration with radiology PACS and breast-imaging clinics, but they leave large gaps for women who move, change insurers, or receive mammograms outside early-adopter networks. Putting Clairity Breast on Everlywell’s platform is a distribution bet: the same company that sells at-home collection kits and virtual care experiences can offer an AI risk readout beside colon cancer screening, HPV self-collection for cervical cancer screening, and multi-cancer early detection access already in its portfolio. Everlywell claims nearly one billion personalized health insights delivered and care transformed for over sixty million people, with an estimated one in ninety-four U.S. households receiving an Everlywell test in 2025. Those scale claims are marketing figures, but they explain why Clairity would trade limited hospital rollouts for a consumer channel with clinician oversight.
Clinicians should still treat AI risk scores as inputs, not autonomous diagnoses. Image-derived risk can complement—not replace—family history, genetic testing, breast density discussions, and shared decision-making about supplemental MRI or medication. PromptCrates has tracked adjacent regulatory movement in FDA discussion of generative AI-enabled medical devices, which sits in a different product class than Clairity’s De Novo-authorized risk software but signals how closely U.S. regulators are watching AI that touches clinical decisions. Buyers and health plans evaluating Everlywell’s offer should ask how mammogram files are transferred securely, how model updates are versioned after De Novo authorization, and how false reassurance or unnecessary anxiety will be handled in patient messaging.
Questions patients and providers should ask
Women considering the product should confirm whether their recent mammogram meets the qualifying criteria and whether their local clinic will release images to Everlywell’s workflow. They should ask what a high-risk result practically changes—earlier follow-up, specialty referral, or lifestyle counseling—and what a low-risk result does not rule out. Providers should request the evidence package behind the De Novo authorization, understand how scores map to NCCN pathways from age thirty-five upward, and document how AI-assisted risk fits into existing breast clinic protocols. Health systems that already use Clairity inside radiology may need clear policies so consumer-channel results do not conflict with in-house workflows.
For the broader health-AI market, the launch is a case study in moving from authorization to access. Many FDA-cleared or authorized imaging AIs remain stuck in pilot wards; pairing with a consumer diagnostics brand is one path to wider reach if clinical review stays intact. Watch whether Everlywell publishes real-world uptake and outcome metrics, whether additional imaging centers join the qualifying mammogram network, and whether payers treat Clairity Breast as a reimbursable adjunct to screening. The companies’ shared message is that risk information latent in mammograms should be available nationally—not only in a handful of early sites—and that AI can surface it without turning the product into a cancer detector. That distinction between risk estimation and diagnosis is the one patients must hear clearly every time a result is released.
Primary reporting for this article: Everlywell and Clairity’s 1 October 2026 Business Wire announcement as carried by FinancialContent. Anchored facts include the nationwide consumer launch date, FDA De Novo authorization in May 2025, NCCN guideline inclusion, the 85% no-family-history statistic stated by the companies, prior limited health-system availability, validation cohort sizes, the twelve-month mammogram requirement, licensed-provider review, and the explicit statement that Clairity Breast does not detect cancer.
